Clinical Trials on Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer in Canada
Total 307 results
-
MedSIRHoffmann-La RocheCompletedAdvanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast CancerSpain, France, United Kingdom, Germany, Italy
-
AHS Cancer Control AlbertaTom Baker Cancer CentreWithdrawnMetastatic Triple Negative Breast CancerCanada
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
AstraZenecaCompletedBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast CancerBelgium, Canada, Austria, Australia
-
SOLTI Breast Cancer Research GroupRecruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | HER2-negative Breast CancerSpain
-
AstraZenecaActive, not recruitingMetastatic Triple Negative Breast CancerUnited States, Belgium, Italy, Spain, United Kingdom, Canada, Czechia, Poland, France, Korea, Republic of, Germany, Taiwan, Portugal, Netherlands, Ireland
-
AHS Cancer Control AlbertaNot yet recruitingBreast Cancer Triple NegativeCanada
-
Celldex TherapeuticsCompletedMetastatic gpNMB Over-expressing Triple Negative Breast CancerUnited States, France, Spain, Italy, Canada, Germany, Australia, Belgium, United Kingdom
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Fudan UniversityNot yet recruitingNeoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast CancerChina
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedAdvanced, Androgen Receptor Positive Triple Negative Breast CancerUnited States, Spain, Belgium, Canada, Ireland, United Kingdom, Italy
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Ottawa Hospital Research InstituteCompleted
-
Novartis PharmaceuticalsCompletedTriple-negative Breast CancerBelgium, Italy, Japan, Taiwan, United States, Australia, Singapore, Spain, Germany, Korea, Republic of, Argentina, Canada, France, Hungary, Israel, Lebanon, Thailand
-
Jewish General HospitalExactis InnovationRecruiting
-
Sermonix Pharmaceuticals Inc.Linical Accelovance GroupActive, not recruitingLocally Advanced or Metastatic Breast CancerUnited States, Canada, Israel
-
Canadian Cancer Trials GroupUniversity Health Network, Toronto; AstraZenecaActive, not recruitingBreast CancerCanada
-
Hoffmann-La RocheCompletedTriple-negative Breast CancerUnited States, Korea, Republic of, Canada, United Kingdom, Belgium, Brazil, Germany, Taiwan, Australia, Japan, Spain, Poland, Italy
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerFrance, Canada, Israel, Italy, Argentina, Brazil, China, Croatia, Germany, Greece, Slovakia, Turkey, Saudi Arabia, Japan, India, Spain, United States, Czechia, Romania, United Kingdom, Morocco, South Africa, Vietnam, Russian Federation
-
Hoffmann-La RocheActive, not recruitingTriple-Negative Breast CancerItaly, Portugal, Slovenia, Spain, Romania, France, Czechia, Peru, Argentina, Chile, Hungary, Mexico, Poland
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerIsrael, United States, Australia, Korea, Republic of, Belgium, Argentina, Denmark, Finland, Italy, Portugal, Spain, Taiwan, Thailand, Japan, United Kingdom, Brazil, Canada, Colombia, Mexico, France, Costa Rica, Switzerland, Czechia, P... and more
-
Hoffmann-La RocheRecruitingLocally Advanced or Metastatic Breast CancerFrance, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, Turkey, United Kingdom, Kenya, Hungary, Poland, Colombia, India, Oman, Uganda, United Arab... and more
-
AstraZenecaRecruitingLocally Advanced (Inoperable) or Metastatic Breast CancerSpain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Brazil, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Poland, Sweden, Italy
-
Cantargia ABSpanish Breast Cancer Research GroupRecruitingTriple Negative Breast CancerSpain
-
Gilead SciencesRecruitingStage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast CancerTaiwan, Korea, Republic of, Greece, Spain, United States, Israel, France, Japan, Belgium, Poland, China, Singapore, Australia, Hungary, Czechia, Italy, South Africa, Hong Kong, Chile, Brazil, Argentina, Austria, Canada, Germany, Portugal, United Kingdom
-
Jewish General HospitalExactis Innovation; Genome QuebecCompletedTriple Negative Breast CancerCanada, United States
-
Bristol-Myers SquibbJanssen Biotech, Inc.CompletedAdvanced CancerUnited States, Switzerland, France, Puerto Rico, Italy, Germany, Australia, Canada, Spain
-
Spanish Breast Cancer Research GroupAstraZenecaRecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerSpain
-
VelosBio Inc.CompletedGastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditionsUnited States, Canada
-
MedSIRGilead SciencesActive, not recruitingBreast Cancer | Triple Negative Breast CancerSpain
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
AstraZenecaActive, not recruitingLocally Advanced (Inoperable) or Metastatic Breast CancerUnited States, Italy, Spain, Belgium, Hungary, Poland, Canada, France, Germany, Korea, Republic of, Japan, Peru, Russian Federation, United Kingdom, China, Taiwan, Israel, Australia, Argentina
-
AstraZenecaSWOG Clinical Trials Partnerships; Daiichi SankyoRecruitingBreast CancerUnited States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
-
Hoffmann-La RocheCompletedTriple Negative Breast CancerUnited States, Korea, Republic of, Belgium, Canada, Germany, United Kingdom, Argentina, Australia, Brazil, Finland, France, Greece, Hungary, Poland, Slovenia, Spain, Taiwan, Turkey, Japan, Singapore, Colombia, Bosnia and Herzegovina, Guatema... and more
-
NSABP Foundation IncHoffmann-La Roche; Genentech, Inc.Active, not recruitingTriple Negative Breast CancerUnited States, Canada
-
AbbVieNSABP Foundation Inc; German Breast Group; US Oncology Research; Grupo Espanol...CompletedTriple Negative Breast CancerUnited States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
Hoffmann-La RocheCompletedBreast CancerUnited States, Korea, Republic of, Canada, United Kingdom, Australia, Belgium, Brazil, France, Slovenia, Spain, Taiwan, Japan, Italy, Argentina, India, Germany, Hungary, Russian Federation, Singapore, Ukraine, Costa Rica, Czechia, G... and more
-
Gilead SciencesCompletedBreast CancerUnited States, Canada, Spain, France, Belgium, United Kingdom, Germany
-
Sunnybrook Health Sciences CentreHarvard UniversityUnknownBreast Neoplasm | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Brain MetastasesCanada
-
Ontario Clinical Oncology Group (OCOG)Juravinski Cancer Centre FoundationCompleted
-
AstraZenecaCompletedMetastatic Breast Cancer | Locally Advanced Breast CancerSweden, United States, Russian Federation, South Africa, United Kingdom, Germany, Hungary, Canada, Belgium, Denmark, Israel, Argentina, France, Brazil, Spain
-
AVEO Pharmaceuticals, Inc.Astellas Pharma IncTerminatedTriple Negative Breast CancerGermany, Taiwan, Spain, Ukraine, Australia, Korea, Republic of, Canada, United States, Italy, Bahamas
-
PfizerCompletedNeoplasmUnited States, Spain, Canada, Italy, United Kingdom
-
Sunnybrook Health Sciences CentreCompletedLocally Advanced Breast CancerCanada
-
AstraZenecaDaiichi SankyoRecruitingBreast CancerUnited States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingNSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK MutationUnited States, Canada
-
GlaxoSmithKlineActive, not recruitingNeoplasms, BreastUnited States, Argentina, France, Netherlands, Finland, Spain, Israel, Poland, Romania, Mexico, Canada, Belgium, Germany, Hungary, Portugal, United Kingdom, Ireland, Australia, Italy, Brazil, Japan, Austria, Russian Federation, South... and more